Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.
Azzaroli
Francesco
F
Department of Internal Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna. azzaroli@med.unibo.it
Accogli
Esterita
E
Nigro
Giovanni
G
Trere
Davide
D
Giovanelli
Silvia
S
Miracolo
Anna
A
Lodato
Francesca
F
Montagnani
Marco
M
Tamé
Mariarosa
M
Colecchia
Antonio
A
Mwangemi
Constance
C
Festi
Davide
D
Roda
Enrico
E
Derenzini
Massimo
M
Mazzella
Giuseppe
G
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008113:Liver Neoplasms / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009697:Nucleolus Organizer Region; D011446:Prospective Studies; D012254:Ribavirin / Q000008:administration & dosage*; D016622:Silver Staining
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons